ATE538796T1 - Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit - Google Patents
Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheitInfo
- Publication number
- ATE538796T1 ATE538796T1 AT07838507T AT07838507T ATE538796T1 AT E538796 T1 ATE538796 T1 AT E538796T1 AT 07838507 T AT07838507 T AT 07838507T AT 07838507 T AT07838507 T AT 07838507T AT E538796 T1 ATE538796 T1 AT E538796T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- treatment
- alzheimer
- disease
- pyrrolidine
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 239000002439 beta secretase inhibitor Substances 0.000 title 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84640006P | 2006-09-21 | 2006-09-21 | |
| PCT/US2007/020303 WO2008036316A2 (en) | 2006-09-21 | 2007-09-19 | Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE538796T1 true ATE538796T1 (de) | 2012-01-15 |
Family
ID=39201073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07838507T ATE538796T1 (de) | 2006-09-21 | 2007-09-19 | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8143405B2 (de) |
| EP (1) | EP2077719B1 (de) |
| JP (1) | JP2010504330A (de) |
| AT (1) | ATE538796T1 (de) |
| AU (1) | AU2007297627A1 (de) |
| CA (1) | CA2664130A1 (de) |
| WO (1) | WO2008036316A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101868457B (zh) | 2007-09-24 | 2013-02-13 | 科门蒂斯公司 | 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物 |
| EP2215048B1 (de) * | 2007-10-31 | 2015-10-28 | Merck Sharp & Dohme Corp. | Antagonisten des p2x3-rezeptors zur behandlung von schmerzen |
| US20130102593A1 (en) * | 2008-10-10 | 2013-04-25 | Geoffrey M. Bilcer | Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
| EP2411000A4 (de) * | 2009-03-25 | 2012-09-19 | Comentis Inc | Pyrrolidin-verbindungen zur hemmung der beta-secretase-wirkung und anwendungsverfahren dafür |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US11512072B2 (en) | 2018-04-19 | 2022-11-29 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using azetidines |
| EP4232425A4 (de) * | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1-inhibitoren und verwendungen davon |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0214295A (pt) | 2001-11-19 | 2004-11-09 | Elan Pharm Inc | Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto |
| JP3897602B2 (ja) * | 2002-01-28 | 2007-03-28 | ヤンマー株式会社 | ガス機関の燃料供給装置 |
| AU2003276047A1 (en) | 2002-06-17 | 2003-12-31 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| US7115652B2 (en) | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| DE60329316D1 (de) | 2002-11-12 | 2009-10-29 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| US7166624B2 (en) * | 2002-12-18 | 2007-01-23 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
| JP2006528694A (ja) * | 2003-05-13 | 2006-12-21 | スミスクライン ビーチャム コーポレーション | ナフチリジンインテグラーゼインヒビター |
| JP2007516207A (ja) | 2003-06-30 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤 |
| JP2007522088A (ja) | 2003-07-01 | 2007-08-09 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療用フェニルカルボン酸ベータセクレターゼ阻害剤 |
| WO2005032471A2 (en) | 2003-10-03 | 2005-04-14 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2546142A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| JP2007517781A (ja) | 2003-12-19 | 2007-07-05 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病治療用のフェニルアミドおよびピリジルアミド系β−セクレターゼ阻害薬 |
| US7847100B2 (en) | 2004-04-20 | 2010-12-07 | Merck, Sharp & Dohme, Inc. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| AU2005236063A1 (en) | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease |
| EP1758854B1 (de) * | 2004-06-15 | 2014-07-16 | Merck Sharp & Dohme Corp. | Als beta-sekretase-inhibitoren für die behandlung von alzheimer-krankheit geeignete pyrrolidin-3-yl-verbindungen |
| US20070060589A1 (en) * | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| PE20071144A1 (es) * | 2006-03-21 | 2008-01-10 | Schering Corp | COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3) |
| WO2008011130A2 (en) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
-
2007
- 2007-09-19 CA CA002664130A patent/CA2664130A1/en not_active Abandoned
- 2007-09-19 AT AT07838507T patent/ATE538796T1/de active
- 2007-09-19 US US12/311,158 patent/US8143405B2/en active Active
- 2007-09-19 WO PCT/US2007/020303 patent/WO2008036316A2/en not_active Ceased
- 2007-09-19 JP JP2009529223A patent/JP2010504330A/ja not_active Withdrawn
- 2007-09-19 AU AU2007297627A patent/AU2007297627A1/en not_active Abandoned
- 2007-09-19 EP EP07838507A patent/EP2077719B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007297627A1 (en) | 2008-03-27 |
| EP2077719B1 (de) | 2011-12-28 |
| WO2008036316A3 (en) | 2008-11-06 |
| JP2010504330A (ja) | 2010-02-12 |
| WO2008036316A2 (en) | 2008-03-27 |
| US8143405B2 (en) | 2012-03-27 |
| EP2077719A2 (de) | 2009-07-15 |
| US20100041667A1 (en) | 2010-02-18 |
| EP2077719A4 (de) | 2010-12-08 |
| CA2664130A1 (en) | 2008-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE396973T1 (de) | Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| EA200870380A1 (ru) | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета | |
| WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
| WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| WO2005065195A3 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| EA200802054A1 (ru) | Ингибиторы фермента | |
| ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
| CY1111086T1 (el) | Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace) | |
| DE60330485D1 (de) | Zur behandlung von diabetes | |
| WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie | |
| BRPI0517435A (pt) | triazóis úteis como inibidores de proteìna cinase | |
| EP2077719A4 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2007058862A3 (en) | Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| ATE549923T1 (de) | Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer |